Paul Fleming
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis, Cancer-related Molecular Pathways, Cancer Treatment and Pharmacology, Microbial Natural Products and Biosynthesis
Most-Cited Works
- → Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer(2010)490 cited
- → A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment(2018)441 cited
- → Precision Targeted Therapy with BLU-667 for RET-Driven Cancers(2018)388 cited
- → Parallel synthesis of 3-aminoimidazo[1,2-a]pyridines and pyrazines by a new three-component condensation(1998)363 cited
- → Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy(2010)271 cited
- → Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit(2010)145 cited
- → Biosynthesis of taxoids. Mode of formation of the taxol side chain(1993)66 cited
- → Genetic transformation of mature Taxus: an approach to genetically control the in vitro production of the anticancer drug, taxol(1994)62 cited
- → Biosynthesis of Taxoids. Mode of Attachment of the Taxol Side Chain(1994)44 cited
- → Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea(2011)41 cited